Renoprotective effects of gamma-aminobutyric acid on cisplatin-induced acute renal injury in rats

Badreldin H. Ali, Suhail Al-Salam, Mohammed Al Za'abi, Khalid A. Al Balushi, Ahmed S. Almahruqi, Somyia Beegam, Intisar Al-Lawatia, Mostafa I. Waly, Abderrahim Nemmar

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To investigate the effect of gamma-aminobutyric acid (GABA) on acute renal injury (ARI), we used here a rat model of acute tubular necrosis induced by the anticancer drug cisplatin (CP). GABA was given orally (100 or 500 mg/kg/day for ten consecutive days), and on the 6th day, some of the treated rats were also injected intraperitoneally with either saline or CP (6 mg/kg). Four days after CP treatment, urine was collected from all rats, which were then anaesthetized for blood pressure and renal blood flow monitoring. This was followed by intravenous injection of norepinephrine for the assessment of renal vasoconstrictor responses. Thereafter, blood and kidneys were collected for measurement of several functional, biochemical and structural parameters. GABA treatment (at 500 but not 100 mg/kg) significantly mitigated all the measured physiological and biochemical indices. Sections from saline- and GABA-treated rats showed apparently normal proximal tubules. However, kidneys of CP-treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with GABA (500 mg/kg). The concentration of platinum in the cortical tissues was not significantly altered by GABA treatment. The results suggested that GABA can ameliorate CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies, GABA may be considered a potentially useful nephroprotective agent in CP-induced ARI.

Original languageEnglish
Pages (from-to)62-68
Number of pages7
JournalBasic and Clinical Pharmacology and Toxicology
Volume116
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Acute Kidney Injury
gamma-Aminobutyric Acid
Cisplatin
Rats
Kidney
Blood
Necrosis
Renal Circulation
Blood pressure
Vasoconstrictor Agents
Platinum
Intravenous Injections
Toxicology
Norepinephrine
Therapeutics
Urine
Pharmacology
Tissue
Blood Pressure
Monitoring

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology
  • Medicine(all)

Cite this

Renoprotective effects of gamma-aminobutyric acid on cisplatin-induced acute renal injury in rats. / Ali, Badreldin H.; Al-Salam, Suhail; Al Za'abi, Mohammed; Al Balushi, Khalid A.; Almahruqi, Ahmed S.; Beegam, Somyia; Al-Lawatia, Intisar; Waly, Mostafa I.; Nemmar, Abderrahim.

In: Basic and Clinical Pharmacology and Toxicology, Vol. 116, No. 1, 01.01.2015, p. 62-68.

Research output: Contribution to journalArticle

@article{ff30c89b7585424fa7780613e9f57838,
title = "Renoprotective effects of gamma-aminobutyric acid on cisplatin-induced acute renal injury in rats",
abstract = "To investigate the effect of gamma-aminobutyric acid (GABA) on acute renal injury (ARI), we used here a rat model of acute tubular necrosis induced by the anticancer drug cisplatin (CP). GABA was given orally (100 or 500 mg/kg/day for ten consecutive days), and on the 6th day, some of the treated rats were also injected intraperitoneally with either saline or CP (6 mg/kg). Four days after CP treatment, urine was collected from all rats, which were then anaesthetized for blood pressure and renal blood flow monitoring. This was followed by intravenous injection of norepinephrine for the assessment of renal vasoconstrictor responses. Thereafter, blood and kidneys were collected for measurement of several functional, biochemical and structural parameters. GABA treatment (at 500 but not 100 mg/kg) significantly mitigated all the measured physiological and biochemical indices. Sections from saline- and GABA-treated rats showed apparently normal proximal tubules. However, kidneys of CP-treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with GABA (500 mg/kg). The concentration of platinum in the cortical tissues was not significantly altered by GABA treatment. The results suggested that GABA can ameliorate CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies, GABA may be considered a potentially useful nephroprotective agent in CP-induced ARI.",
author = "Ali, {Badreldin H.} and Suhail Al-Salam and {Al Za'abi}, Mohammed and {Al Balushi}, {Khalid A.} and Almahruqi, {Ahmed S.} and Somyia Beegam and Intisar Al-Lawatia and Waly, {Mostafa I.} and Abderrahim Nemmar",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/bcpt.12291",
language = "English",
volume = "116",
pages = "62--68",
journal = "Basic and Clinical Pharmacology and Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Renoprotective effects of gamma-aminobutyric acid on cisplatin-induced acute renal injury in rats

AU - Ali, Badreldin H.

AU - Al-Salam, Suhail

AU - Al Za'abi, Mohammed

AU - Al Balushi, Khalid A.

AU - Almahruqi, Ahmed S.

AU - Beegam, Somyia

AU - Al-Lawatia, Intisar

AU - Waly, Mostafa I.

AU - Nemmar, Abderrahim

PY - 2015/1/1

Y1 - 2015/1/1

N2 - To investigate the effect of gamma-aminobutyric acid (GABA) on acute renal injury (ARI), we used here a rat model of acute tubular necrosis induced by the anticancer drug cisplatin (CP). GABA was given orally (100 or 500 mg/kg/day for ten consecutive days), and on the 6th day, some of the treated rats were also injected intraperitoneally with either saline or CP (6 mg/kg). Four days after CP treatment, urine was collected from all rats, which were then anaesthetized for blood pressure and renal blood flow monitoring. This was followed by intravenous injection of norepinephrine for the assessment of renal vasoconstrictor responses. Thereafter, blood and kidneys were collected for measurement of several functional, biochemical and structural parameters. GABA treatment (at 500 but not 100 mg/kg) significantly mitigated all the measured physiological and biochemical indices. Sections from saline- and GABA-treated rats showed apparently normal proximal tubules. However, kidneys of CP-treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with GABA (500 mg/kg). The concentration of platinum in the cortical tissues was not significantly altered by GABA treatment. The results suggested that GABA can ameliorate CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies, GABA may be considered a potentially useful nephroprotective agent in CP-induced ARI.

AB - To investigate the effect of gamma-aminobutyric acid (GABA) on acute renal injury (ARI), we used here a rat model of acute tubular necrosis induced by the anticancer drug cisplatin (CP). GABA was given orally (100 or 500 mg/kg/day for ten consecutive days), and on the 6th day, some of the treated rats were also injected intraperitoneally with either saline or CP (6 mg/kg). Four days after CP treatment, urine was collected from all rats, which were then anaesthetized for blood pressure and renal blood flow monitoring. This was followed by intravenous injection of norepinephrine for the assessment of renal vasoconstrictor responses. Thereafter, blood and kidneys were collected for measurement of several functional, biochemical and structural parameters. GABA treatment (at 500 but not 100 mg/kg) significantly mitigated all the measured physiological and biochemical indices. Sections from saline- and GABA-treated rats showed apparently normal proximal tubules. However, kidneys of CP-treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with GABA (500 mg/kg). The concentration of platinum in the cortical tissues was not significantly altered by GABA treatment. The results suggested that GABA can ameliorate CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies, GABA may be considered a potentially useful nephroprotective agent in CP-induced ARI.

UR - http://www.scopus.com/inward/record.url?scp=84919848423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919848423&partnerID=8YFLogxK

U2 - 10.1111/bcpt.12291

DO - 10.1111/bcpt.12291

M3 - Article

VL - 116

SP - 62

EP - 68

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

SN - 1742-7835

IS - 1

ER -